Abstract
We report two cases of late recurrence of eruptive locoregional metastatic melanoma occurring 6 and 9 years after definitive surgical treatment. Each case (stage IB and IA) occurred after initiation of the subcutaneous anti-tumor necrosis factor medications etanercept and adalimumab, respectively. We discuss the association of immune suppression and melanoma. These cases illustrate a previously unrecognized and potentially causal relationship between tumor necrosis factor-alpha inhibition and reactivation of latent melanoma.
MeSH terms
-
Adalimumab
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / adverse effects*
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Antirheumatic Agents / administration & dosage
-
Antirheumatic Agents / adverse effects*
-
Antirheumatic Agents / therapeutic use
-
Arthritis, Rheumatoid / drug therapy
-
Etanercept
-
Female
-
Humans
-
Immunoglobulin G / administration & dosage
-
Immunoglobulin G / adverse effects*
-
Immunoglobulin G / therapeutic use
-
Injections, Subcutaneous
-
Melanoma / chemically induced*
-
Melanoma / diagnostic imaging
-
Melanoma / pathology
-
Melanoma / secondary
-
Middle Aged
-
Neoplasm Recurrence, Local / chemically induced*
-
Positron-Emission Tomography
-
Psoriasis / drug therapy
-
Receptors, Tumor Necrosis Factor / administration & dosage
-
Receptors, Tumor Necrosis Factor / therapeutic use
-
Skin Neoplasms / chemically induced*
-
Skin Neoplasms / diagnostic imaging
-
Skin Neoplasms / pathology
-
Skin Neoplasms / secondary
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antirheumatic Agents
-
Immunoglobulin G
-
Receptors, Tumor Necrosis Factor
-
Tumor Necrosis Factor-alpha
-
Adalimumab
-
Etanercept